SOURCE: Healtheuniverse Inc.

December 05, 2006 14:37 ET

Healtheuniverse Announces Appointment of Richard Tabizon to Managing Director of Asian Operations

Company Positioned to Perform First Human Clinical Trials Using Proprietary Adult Stem Cell Technology

COVINA, CA -- (MARKET WIRE) -- December 5, 2006 -- Healtheuniverse Inc. (PINKSHEETS: HLUN), a diversified biotechnology development firm specializing in the development and commercialization of patented biopharmaceutical and biomedical products, announced today that Richard Tabizon has been appointed Managing Director of Asian Operations. He will be positioned in the Company's Singapore headquarters overseeing the expansion of pre-clinical and clinical adult stem cell development. His responsibilities also include the management of corporate operations in Singapore and throughout Asia.

Scientific protocols have been prepared for the first human clinical trials using the company's proprietary stem cell technology. This technology uses adipose tissue, or fat which can be used as an abundant source of stem cells for tissue engineering and regenerative medicine. The Company intends to sell this proprietary technology to physicians, clinicians and medical organizations through a packaged product line and licensing agreements within the worldwide regenerative medicine market which is estimated to grow to $500 billion by 2010.

Richard D. Tabizon, recently Vice President and Registered Principal with Emmett A. Larkin Company, Inc., has more than 10 years of Financial and Regulatory Compliance expertise with a strong emphasis on Risk Management. Mr. Tabizon has extensive experience in navigating the regulatory landscape of the National Association of Securities Dealers the Securities and Exchange Commission along with various State Regulators. Over the years Mr. Tabizon has cultivated an extensive network of worldwide contacts in the financial community. Prior to joining Emmett A. Larkin Company, Inc. Mr. Tabizon was the Chief Compliance Officer for PMB Securities Corp., a wholly owned subsidiary of Pacific Mercantile Bank, a publicly traded company. While at PMB Securities Corp. Mr. Tabizon created comprehensive investment platforms that allowed his retail staff to effectively increase firm profitability. Mr. Tabizon is in the process of obtaining his Doctor of Jurisprudence from American Heritage University School of Law, San Bernardino.

About HEALTHeUNIVERSE Inc.

HEALTHeUNIVERSE Inc. is a biotechnology development firm specializing in the development and commercialization of patented Biopharmaceutical and Biomedical products. We are engaged in research and development of regenerative medicine therapies using non-embryonic adult stem cells for use in plastic, reconstructive, orthopedic, vascular, and cardiac surgery. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in the most profitable commercial applications. More information on Healtheuniverse is available online at http://healtheuniverse.com/

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Healtheuniverse Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact Information

  • For more information, please contact:
    Healtheuniverse Inc.
    Investor Relations
    800-719-7424
    Email Contact